Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 70Lymphoid 63Myeloid 25Plasma cell 16Dermatologic 16Classical hematology 12Genitourinary 10Gastrointestinal 9Gynecologic 7Sarcoma 5Breast 5Head & Neck 4Thoracic 3CNS 3Tumor-Agnostic 2Other solid neoplasm 2Other neoplasm 2

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × fludarabine phosphate × Other solid neoplasm × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡